Jiangsu Jibeier Pharmaceutical (688566) Q1 2026 earnings summary

Executive summary

• Revenue increased 12.2% year-over-year to ¥226.4 million in Q1 2026.

• Net profit attributable to shareholders declined 15.21% year-over-year to ¥42.0 million.

• Operating cash flow turned negative at -¥22.0 million, down from ¥44.0 million last year.

Financial highlights

• Total assets rose slightly to ¥2.72 billion, up 0.21% from year-end 2025.

• Shareholders’ equity increased 2.11% to ¥2.48 billion.

• Basic and diluted EPS both fell to ¥0.21, down 16% year-over-year.

• R&D investment decreased 16.68% to ¥13.3 million, now 5.86% of revenue.

Key financial ratios and metrics

• Gross margin and operating margin not explicitly stated, but profit margins declined.

• Weighted average ROE dropped to 1.71%, down 0.47 percentage points year-over-year.